

THROMBOSIS
& HEM

9th

International Conference on
**THROMBOSIS
& HEMOSTASIS
ISSUES IN CANCER**

April 13-15, 2018

Bergamo, Italy

Preliminary program - ICTHIC April 13-15, 2018

Friday April 13th 2018

10:30 – 10:45 Congress Opening: A Falanga, FR Rickles, B Brenner

10:45 – 13:00 **Plenary Session 1: Epidemiology of Thrombosis in cancer**

Chairs: T.B.A.

- 1. M Carrier (Canada). Revisiting Occult Cancer Screening in patients with unprovoked Venous Thromboembolism**
- 2. JB Hansen (Norway). Prothrombotic genotypes and risk of venous thromboembolism in cancer**
- 3. HA Liebman (USA). Venous thromboembolism and prognosis in cancer**
- 4. B Brenner (Israel). Arterial Thrombosis and Cancer**

Oral Communications

13:00 – 14:00 Lunch sessions



www.ictthic.com



14:00 – 14:20 **Coffee and pastries**

14:20 – 16:35 **Plenary Session 2: Candidate targets for CAT prevention**

Chairs: T.B.A.

1. J Palumbo (USA). The role of hemostatic factors in cancer progression
2. C Ay (Austria). Podoplanin as potential target for prevention of VTE in cancer
3. C Dubois (France). Interactions between platelets and tumor related microparticles
4. N Mackman (USA). Mouse models of cancer-associated thrombosis

Oral Communications

16:35- 17:05 **Coffee Break**



17:05 – 18:05 Plenary Lecture: 5th Simon Karparkin Memorial Lecture

Chairs: A Falanga (Italy); B Brenner (Israel); FR Rickles (USA)

Introduction to Lecture: FR Rickles (USA)

Tumor angiogenesis: past, present and future

R Giavazzi (Italy)

18:05 – 19:55 Plenary Session 3: Predictors and clinical risk models for VTE and prognosis in cancer

Chairs: TBA

- 1- A Falanga (Italy). Biomarkers in CAT and cancer progression
- 2- G Gerotziapas (France). Updated clinical model for VTE prediction in medical patients
- 3- AA Khorana (USA). Risk prediction in cancer-associated thrombosis: Appraising the first decade and developing the future

Oral Communications

20.00 – 21.00 Welcome Reception

THROMBOSIS
& HEM

9th

International Conference on
**THROMBOSIS
& HEMOSTASIS
ISSUES IN CANCER**

April 13-15, 2018

Bergamo, Italy

Saturday April 14th 2018

8:30 – 10:45 Plenary session 4: Dealing with bleeding in cancer

Chairs: TBA

1. **M Levi (The Netherlands). Clinical characteristics of DIC in patients with solid or hematological cancers.**
2. **V Mathews (India). Mechanisms and management of coagulopathy in APL**
3. **G Castaman (Italy). Management of thrombocytopenia in cancer**
4. **N Mutch (UK). Newer antithrombotic agents targeting novel mechanisms that might not increase bleeding in cancer**

Oral Communications

10:45 – 11:15 Coffee break



11:15 – 13:30 Plenary Session 5: Complex hemostatic conditions

Chairs: TBA

- 1- G Kenet (Israel). Venous thromboembolism in childhood lymphoblastic leukemia
- 2- S Mantha (USA). Predictive factors of fatal bleeding in APL
- 3- I Weitz (USA). Chemotherapy and microangiopathies
- 4- P Gresele (Italy). Anti-platelet treatments in cancer: basic and clinical research

Oral Communications

13:30 – 14:30 Coffee break

14:30 – 16:30 Poster sessions with coffee and pastries



16:30 – 18:50 Plenary Session 6: Thromboprophylaxis in cancer

Chairs: TBA

- 1- G Lyman (USA). Venous Thromboembolism in Hospitalized Cancer Patients: Update on 16 years of data from US
- 2- P Mismetti (France). Findings from the recent published clinical trials on thromboprophylaxis in cancer
- 3- W Ageno (Italy). Antidotes for target specific oral anticoagulants: what news?

Presentation of ongoing clinical trials on prophylaxis (7 + 3-5 minutes/each)

- 1- AA Khorana (USA). CASSINI study
- 2- M Carrier (Canada). AVERT Study
- 3- J Zwicker (USA). Cancer Associated Thrombosis and Isoquercetin (CAT IQ Study)

Oral Communications



Sunday April 15th 2018

8:30 – 10:45 Plenary Session 7: Exploring the relationship between hemostasis and cancer: New insights

Chairs: TBA

1. J Rak (Canada). Oncogenes as drivers of prothrombotic phenotype in cancer
2. C Graf (Germany). Tissue Factor as mediator between coagulation and signaling in cancer
3. AK Olsson (Sweden). NET-osis, platelets and cancer
4. Y Nadir (Israel). Novel strategies of coagulation inhibition for reducing tumor growth and angiogenesis

Oral Communications

10:45 – 11:45 DEBATE: Are new anticoagulants a safe and reasonable alternative to low molecular heparins?

Chairs: TBA

YES: H. Buller

NO: S. Noble

THROMBOSIS
& HEM

9th

International Conference on
**THROMBOSIS
& HEMOSTASIS
ISSUES IN CANCER**

April 13-15, 2018

Bergamo, Italy

11:45- 12:45 Brunch

**12:45 – 15:00 Plenary Session 8: Treatment of VTE in cancer patients:
Advances and unmet needs**

Chairs: TBA

- 1- AY Lee (Canada). Overview of VTE treatment in cancer according to clinical guidelines
- 2- G Agnelli (Italy). Treatment of VTE in cancer patients: what news from clinical Trials?
- 3- AJ Kakkar (United Kingdom). VTE management: emerging insights from the GARFIELD VTE registry
- 4- S Schulman (USA). Recurrent venous thromboembolism in cancer patients

Oral Communications

15:00 – 15:15 Concluding Remarks